|

Tirelizumab Clinical Trials

2 actively recruiting trials

Also known as: anti-PD-1 monoclonal antibody

Pipeline

Phase 2: 2

Top Sponsors

  • Ruijin Hospital1
  • Huihua Xiong1

Indications

  • Cancer2
  • TNBC - Triple-Negative Breast Cancer1
  • Esophageal Squamous Cell Carcinoma1
  • Breast Cancer1

Other2 trials

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
Phase 2
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.